Akero Therapeutics Advances in MASH Treatment Trials [Yahoo! Finance]
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Akero Therapeutics is a clinical-stage biotechnology company focused on developing transformational treatments for serious metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH), a severe liver condition. In its third quarter earnings report for 2024, Akero Therapeutics highlighted significant progress in its clinical trials, particularly with the first patient dosed in their Phase 3 SYNCHRONY Outcomes study for the treatment of MASH. The company continues to advance its three-phase SYNCHRONY program, aiming to evaluate the safety and efficacy of its lead candidate, Efruxifermin (EFX), across different patient groups affected by MASH. Key financial metrics from the report indicate that Akero's cash reserves stand at $787.1 million as of September 30, 2024, which the company believes will suffice to fund its ongoing clinical trials through the second half of 2027. The company's research and development expenses saw a notable increase to $72.2 million
Show less
Read more
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- Akero Therapeutics to Present at the Jefferies London Healthcare ConferenceGlobeNewswire
- Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024GlobeNewswire
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law FirmPR Newswire
AKRO
Earnings
- 11/8/24 - Miss
AKRO
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form SC
- 11/8/24 - Form 4
- AKRO's page on the SEC website